logo Hematology/Oncology Research Studies: Open for Enrollment Date: 07/19/19


NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes

NCT#/Phase: NCT03233204
Phase 2
IRB#: 2017-095h
Description: This is a subprotocol of the MATCH trial APEC1621 and is a phase 2 trial of olaparib in children with relapsed or refractory solid tumors (including non-Hodgkin lymphomas, histiocytoses and CNS involvement) harboring specified defects in DNA damage repair genes. The study aims to determine the objective response rate of Olaparib (Lynparza), a potent orally bioavailable small molecule inhibitor of PARP.
Inclusion: Individuals who are between 12 months and 21 years of age and given a therapy assignment to MATCH to APEC1621H.
Enrollment Status: Open for enrollment
Sponsor: Children's Oncology Group
Principal Investigator(s): Carla Golden, MD
Contact(s): Christine Ho (510-428-3885 x 2609)
Diane Olzewski (510-428-3885 x 3246)
Study Link: https://clinicaltrials.gov/ct2/show/NCT03233204#

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000